Albireo Pharma Inc (NASDAQ:ALBO)

36.75
Delayed Data
As of 4:00pm ET
 -0.09 / -0.24%
Today’s Change
11.26
Today|||52-Week Range
49.00
-2.03%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$723.6M

Company Description

Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Contact Information

Albireo Pharma, Inc.
10 Post Office Square
Boston Massachusetts 02109
P:(857) 254-5555
Investor Relations:

Employees

Shareholders

Other institutional50.73%
Mutual fund holders40.90%
Individual stakeholders21.52%

Top Executives

Ronald H. W. CooperPresident, Chief Executive Officer & Director
Simon John HarfordChief Financial Officer & Treasurer
Jan Peter MattssonChief Scientific Officer, Managing Director-Sweden
Patrick Taylor HornChief Medical Officer
Per-Göran GillbergVice President-Development & Owner